Cargando…

New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity

The substantial progress of the human induced pluripotent stem cell (hiPSC) technologies over the last decade has provided us with new opportunities for cardiovascular drug discovery, regenerative medicine, and disease modeling. The combination of hiPSC with 3D culture techniques offers numerous adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Orsolits, Barbara, Kovács, Zsófia, Kriston-Vizi, János, Merkely, Béla, Földes, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039822/
https://www.ncbi.nlm.nih.gov/pubmed/33854431
http://dx.doi.org/10.3389/fphar.2021.603016
_version_ 1783677676269076480
author Orsolits, Barbara
Kovács, Zsófia
Kriston-Vizi, János
Merkely, Béla
Földes, Gábor
author_facet Orsolits, Barbara
Kovács, Zsófia
Kriston-Vizi, János
Merkely, Béla
Földes, Gábor
author_sort Orsolits, Barbara
collection PubMed
description The substantial progress of the human induced pluripotent stem cell (hiPSC) technologies over the last decade has provided us with new opportunities for cardiovascular drug discovery, regenerative medicine, and disease modeling. The combination of hiPSC with 3D culture techniques offers numerous advantages for generating and studying physiological and pathophysiological cardiac models. Cells grown in 3D can overcome many limitations of 2D cell cultures and animal models. Furthermore, it enables the investigation in an architecturally appropriate, complex cellular environment in vitro. Yet, generation and study of cardiac organoids—which may contain versatile cardiovascular cell types differentiated from hiPSC—remain a challenge. The large-scale and high-throughput applications require accurate and standardised models with highly automated processes in culturing, imaging and data collection. Besides the compound spatial structure of organoids, their biological processes also possess different temporal dynamics which require other methods and technologies to detect them. In this review, we summarise the possibilities and challenges of acquiring relevant information from 3D cardiovascular models. We focus on the opportunities during different time-scale processes in dynamic pharmacological experiments and discuss the putative steps toward one-size-fits-all assays.
format Online
Article
Text
id pubmed-8039822
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80398222021-04-13 New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity Orsolits, Barbara Kovács, Zsófia Kriston-Vizi, János Merkely, Béla Földes, Gábor Front Pharmacol Pharmacology The substantial progress of the human induced pluripotent stem cell (hiPSC) technologies over the last decade has provided us with new opportunities for cardiovascular drug discovery, regenerative medicine, and disease modeling. The combination of hiPSC with 3D culture techniques offers numerous advantages for generating and studying physiological and pathophysiological cardiac models. Cells grown in 3D can overcome many limitations of 2D cell cultures and animal models. Furthermore, it enables the investigation in an architecturally appropriate, complex cellular environment in vitro. Yet, generation and study of cardiac organoids—which may contain versatile cardiovascular cell types differentiated from hiPSC—remain a challenge. The large-scale and high-throughput applications require accurate and standardised models with highly automated processes in culturing, imaging and data collection. Besides the compound spatial structure of organoids, their biological processes also possess different temporal dynamics which require other methods and technologies to detect them. In this review, we summarise the possibilities and challenges of acquiring relevant information from 3D cardiovascular models. We focus on the opportunities during different time-scale processes in dynamic pharmacological experiments and discuss the putative steps toward one-size-fits-all assays. Frontiers Media S.A. 2021-03-29 /pmc/articles/PMC8039822/ /pubmed/33854431 http://dx.doi.org/10.3389/fphar.2021.603016 Text en Copyright © 2021 Orsolits, Kovács, Kriston-Vizi, Merkely and Földes. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Orsolits, Barbara
Kovács, Zsófia
Kriston-Vizi, János
Merkely, Béla
Földes, Gábor
New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity
title New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity
title_full New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity
title_fullStr New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity
title_full_unstemmed New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity
title_short New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity
title_sort new modalities of 3d pluripotent stem cell-based assays in cardiovascular toxicity
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039822/
https://www.ncbi.nlm.nih.gov/pubmed/33854431
http://dx.doi.org/10.3389/fphar.2021.603016
work_keys_str_mv AT orsolitsbarbara newmodalitiesof3dpluripotentstemcellbasedassaysincardiovasculartoxicity
AT kovacszsofia newmodalitiesof3dpluripotentstemcellbasedassaysincardiovasculartoxicity
AT kristonvizijanos newmodalitiesof3dpluripotentstemcellbasedassaysincardiovasculartoxicity
AT merkelybela newmodalitiesof3dpluripotentstemcellbasedassaysincardiovasculartoxicity
AT foldesgabor newmodalitiesof3dpluripotentstemcellbasedassaysincardiovasculartoxicity